Select demographic, clinical, and immunologic correlates within CLAAS cohort.
| Outcome | Predictor | Univariate1 | Covariable | Multivariate2 | ||
|---|---|---|---|---|---|---|
| OR (95% CI) | p | OR (95% CI) | p | |||
| Vital status (alive) | P-ANCA | 7.94 (2.01–31.36) | 0.0036 | Race3 | 5.76 (1.25–26.58) | 0.025 |
| C-ANCA | 0.04 (0.01–0.42) | 0.0018 | Race3 | 0.06 (0.01–0.66) | 0.022 | |
| Purpura/ulcers | Anti-MPO | 5.56 (1.62–19.03) | 0.0092 | NA | NA | NA |
| MSK | Anti-MPO | 7.00 (1.95–25.14) | 0.0034 | ANCA-IF pattern4 | 4.24 (1.04–17.20) | 0.044 |
↵1 Fisher’s exact test, 2-tailed.
↵2 Logistic regression analysis controlling for listed covariables.
↵3 White vs others; Black/African American vs others.
↵4 P-ANCA vs C-ANCA vs A-ANCA. CLAAS: cocaine/levamisole-associated autoimmunity syndrome; ANCA: antineutrophil antibodies; P-ANCA: perinuclear ANCA; C-ANCA: cytoplasmic; MSK: musculoskeletal; IF: immunofluorescence; NA: not assessed.